



Can-Fite BioPharma – Small Molecule Drugs for the Treatment of Liver Diseases

Fishman Pnina

Can-Fite BioPharma Ltd, Kiryat-Matalon, Petach -Tikva, Israel

Can-Fite BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of orally active drugs to treat cancer and inflammatory diseases. Our proprietary drug development pipeline includes several small molecule drug candidates that are designed to target the A₃ adenosine receptor, found to be highly expressed in inflammatory and tumor cells.

CF102 is a highly selective and specific A₃ adenosine receptor agonist, which has been shown to block proliferation and specifically trigger apoptosis in experimental syngeneic and xenograft hepatocellular carcinoma murine models. In addition, CF102 plays a key role in the inhibition of hepatitis C viral replication. CF102 mechanism of action includes de-regulation of the Wnt and the NF-κB signal transduction pathways. CF102 was found to be safe and well tolerated in pre-clinical and Phase I human clinical studies.

In 2009, Can Fite initiated two Phase I/II clinical trials of CF102, designed to evaluate sustained viral response rates in patients with genotype 1 HCV and anti-tumor response in patients with Hepatocellular carcinoma.

CF102 has advantages over other existing drugs for liver diseases in that it has the potential to be developed as an oral drug with high safety profile, targeting exclusively pathological liver cells.